Status:
ACTIVE_NOT_RECRUITING
Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart)
Lead Sponsor:
The Second Hospital of Shandong University
Conditions:
Adenomyosis
in Vitro Fertilization
Eligibility:
FEMALE
20-37 years
Brief Summary
Previous studies have shown that compared with infertile women without adenomyosis, the clinical pregnancy rate, live birth rate and continuous pregnancy rate of women with adenomyosis significantly r...
Detailed Description
Previous studies have shown that compared with infertile women without adenomyosis, the clinical pregnancy rate, live birth rate and continuous pregnancy rate of women with adenomyosis significantly r...
Eligibility Criteria
Inclusion
- Age of all participants ≥ 20 and\< 38 years.
- Receiving IVF treatment because of adenomyosis or other common factor, such as fallopian tube factors.
- Conforming to MUSA criteria.
- Body mass index \< 30 kg/m2.
- The level of AMH ≥ 0.8 ng/ml.
Exclusion
- Uterine fibroids (International Federation of Gynecology and Obstetrics (FIGO) type 0--I--II or type III--IV fibroids \< 3 cm).
- Untreated endometrial polyps, hydrosalpinges or uterine adhesions.
- RSA or RIF.
- Intracytoplasmic sperm injection (ICSI) and preimplantation genetic testing (PGT).
- Concurrent and/or recent involvement in other research within previous 3 months of study
Key Trial Info
Start Date :
June 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2030
Estimated Enrollment :
2241 Patients enrolled
Trial Details
Trial ID
NCT06604091
Start Date
June 30 2024
End Date
January 1 2030
Last Update
August 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Clinical Hospital of Shandong University
Jinan, Shandong, China, 250033